AMAL Therapeutics to publish research outcomes in Cancers

Geneva, Switzerland, October 20, 2022 – AMAL Therapeutics announced today that the latest findings of its research team is on line on the Cancers website. By using an in vitro (THP-1 cell line) and ex vivo model system (human monocyte-derived dendritic cells), the team was able to demonstrate that ATP128 relies on both the cell-penetrating peptide and TLR agonist domain present in the construct to activate the NF-κB and IRF3 pathways, in a self-adjuvanting manner. Importantly, it was demonstrated that ATP128 is the first therapeutic vaccine able to activate human DCs through TLR2 and TLR4.

PDF icon Full article in .pdf

Share this entry

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: